Headlining at Pharmacists for Life International is a low opinion of the FDA’s decision to spend time on this me-too analog of the abortive drug, mifepristone (RU486), and allow the marketing as a morning after pill.
Below is what Pharmer sent to Rob Stein of the Washington post, at his request. It’s possibly not translatable into language understandable by that newspaper’s readers.
On the sidebar and searchable on this blog is further information on Ulipristal acetate, coming soon to the US, for use in underage girls, (without parental consent) and by women who are ill-informed about the drug and its effects.
Reply to request for statement on the impending approval of Ulipristal:
Ulipristal Acetate, according to its developers, can kill embryos and fetuses, and is marketed in Europe as EllaOne. The low dose 30mg form, has been prioritized for approval by the FDA, which would have served us better by adequately addressing the current, rolling shortages of lifesaving and essential medications.
The embryocidal, ulipristal acetate doses may be accumulated by physicians or patients for medical abortions at home, sidestepping the so-called regulation of mifepristone/misoprostil (the other abortion drug). This will lead to additional life-endangering problems for the targeted adolescent girls and women.
The FDA is expected to continue in its long tradition of relegating females to bottom class health care status.
Reply when asked if pharmacists would refuse to dispense it:
Pharmacists were excused from handling mifepristone/misoprostil, and most were relieved to be sheltered from the ethical and legal liabilities.
The majority would not like providing information and dispensing ulipristal, since it is an analog of mifepristone. Expect attempts to force pharmacists to do so.
If you were to juxtapose the issue of severe drug shortages and the approval of this ‘me-too’, abortifacient in a survey of pharmacists, the majority would express the opinion that the FDA is nearly useless.
Personal note to Rob Stein concerning the FDA’s action:
In my place of employment is a gigantic board listing the shortages and outages of essential medications, such as antibiotics, pain relievers, anaesthetics and drugs for sedation.This problem has been significant for years, and has worsened considerably in the last year, impeding our ability to provide vital care for our patients.
The FDA has placed the approval of this duplicate analog of mifepristone ahead of need to address this severe health care issue. My disrespect for the FDA is profound and beyond the ability to verbalize.